Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intravenous Hydrocortisone in Sepsis
NCT06217939Terminated
- Sponsor
- Siriraj Hospital
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydrocortisone in sepsis and septic shock (2 arms), sponsored by Siriraj Hospital. Primary endpoint: 28-day mortality. Started Jun 2024; status: terminated.
02
Drugs
hydrocortisone
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT06217939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217939.